OXBDF (Oxford BioMedica) Moat Score: 5/10 (As of Jul. 02, 2026)


OXBDF Oxford BioMedica PLC OXBDF
72 GF Score
Price $7.93
GF Value $6.84
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica Moat Score?

Oxford BioMedica OXBDF 72 Moat Score is 5 as of Jul. 02, 2026. GuruFocus rates OXBDF with a GF Score™ of 72/100 and a GF Value™ of $6.84 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,400 Biotechnology companies, Oxford BioMedica ranks better than 96.71% on this metric.

Oxford BioMedica has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Oxford BioMedica has Narrow Moat: Oxford BioMedica has a solid narrow moat due to its valuable intellectual property and patents in gene and cell therapy. The company benefits from strong R&D capabilities and some customer switching costs due to specialized products. However, it lacks significant market leadership and brand strength to warrant a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Oxford BioMedica might have Narrow Moat - Solid narrow moat.

Oxford BioMedica  (OTCPK:OXBDF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Oxford BioMedica Moat Score Related Terms

OXBDF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Oxford BioMedica's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioMedica Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Moat Score distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's Moat Score falls into.


OXBDF
72GF Score
Oxford BioMedica PLC OXBDF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Oxford BioMedica (OXBDF) has a Moat Score of 5 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Oxford BioMedica ranks #46 out of 1400 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Oxford BioMedica's Moat Score too high?
Oxford BioMedica's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Oxford BioMedica's value of 5 is 150% above this industry median. Based on the distribution chart, Oxford BioMedica ranks #46 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oxford BioMedica has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #46 out of 1400 companies for Moat Score. This places Oxford BioMedica in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Oxford BioMedica's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxford BioMedica's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioMedica's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.84, compared to a current price of $7.93 — trading 15.9% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Oxford BioMedica's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current Moat Score is 5 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (OXBDF) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of $7.93 is trading 15.9% above its estimated GF Value™ of $6.84. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for OXBDF:

  • Moat Score: 5
  • GF Value™: $6.84 vs. price of $7.93 (15.9% above fair value)
  • GF Score™: 72/100 with 5 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1400)

No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBl:UKOXB:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
72GF Score

Get the complete analysis for OXBDF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.93
Price
$6.84
GF Value